Retatrutide pricing exists in two entirely different universes right now. In the grey market for research peptides, a 10 mg vial costs $60 to $120. If and when retatrutide receives FDA approval, the Eli Lilly brand price is expected to be $800 to $1,200 per month based on the pricing structures established by Zepbound and Mounjaro. The gap between those two numbers — roughly a factor of ten — reflects the difference between unregulated research chemical supply and FDA-approved pharmaceutical manufacturing. Both prices are real. Which one you pay depends entirely on which market you have access to and are willing to use.
Grey Market Vial Pricing
Research chemical vendors currently offer retatrutide as lyophilized powder in sealed vials. A 10 mg vial typically costs $60 to $120, depending on the vendor’s reputation and whether they provide third-party Certificate of Analysis results. A 20 mg vial ranges from $100 to $200. A 30 mg vial ranges from $150 to $300. These prices translate to roughly $2 to $10 per mg of peptide, depending on the vendor and quantity purchased. Bulk purchases of multiple vials often receive volume discounts of 10-20%.
Projected Brand Pricing
Eli Lilly has not announced pricing for the eventual commercial product, but the comparison with Zepbound (tirzepatide) provides a reasonable estimate. Zepbound has a list price of approximately $1,060 per month before insurance. Mounjaro (the same drug, branded for type 2 diabetes) lists at approximately $1,025 per month. Given that retatrutide is a novel triple-agonist compound requiring more complex manufacturing, the price is unlikely to be lower than tirzepatide. A realistic range is $800 to $1,200 per month before insurance coverage or manufacturer savings programs.
Compounding Pharmacy Estimates
Compounded retatrutide — if and when it becomes available through compounding pharmacies — would likely be priced between $200 and $500 per month, based on the current compounding market for tirzepatide and semaglutide. However, the FDA has taken an aggressive stance against compounded GLP-1 drugs when the branded versions are not in shortage, and retatrutide is not yet approved in any form. Compounding access would not exist until after FDA approval, and even then would depend on supply dynamics.
Cost Comparison Across the GLP-1 Class
Ozempic/semaglutide: $935/month list. Mounjaro/tirzepatide: $1,025/month. Zepbound: $1,060/month. Retatrutide (grey market): $60-120 per 10 mg vial. Retatrutide (projected brand): $800-1,200/month. The grey market is dramatically cheaper, but that price comes with substantial risk — no purity guarantee, no dosing accuracy assurance, no medical oversight. The brand price will be comparable to existing GLP-1 drugs, with similar insurance coverage dynamics expected once approved.
What You Actually Pay Per Dose
A 2 mg weekly dose — the starting dose in the TRIUMPH protocol — from a grey market vendor costs roughly $12 to $24 per dose (one-fifth of a 10 mg vial). At the maintenance dose of 12 mg weekly, the cost rises to $72 to $144 per week, or $288 to $576 per month. This is the actual monthly cost range for grey market retatrutide at therapeutic doses, which is lower than the brand list prices of existing GLP-1 drugs but not dramatically so when you consider the quality uncertainty.
Leave a Reply